Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S2). [1]
2026 List, S2.2.4, printed page 8 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity matters
CJC-1295 is discussed as a growth-hormone-releasing-hormone analogue. FDA distinguishes several related forms, including drug-affinity-complex (DAC), non-DAC and salt variants. Evidence for a specified long-acting DAC compound should not be applied automatically to every vial sold as CJC-1295. [2]
What the human trials measured
Teichman and colleagues reported two randomized, blinded, placebo-controlled studies in healthy adults aged 21–61, with 28- and 49-day study periods. The principal findings concerned pharmacokinetics and increases in growth hormone and IGF-1. Hormone elevation is not proof of better recovery, strength, body composition or treatment of disease. No serious adverse reactions were reported in these small short studies. [3]
- The primary study was checked at repository-abstract depth; the linked full PDF could not be read.
Health and product uncertainties
FDA describes injection-site reactions, headache, flushing, transient low blood pressure and increased heart rate in the available evidence. Long-term clinical benefit and safety remain unresolved. Its review also documents marketing of peptide blends, which does not establish composition, efficacy or interchangeability of their ingredients. [2]
What remains uncertain
- Full primary-trial methods and adverse-event tables were not independently read.
- No approval, current product purity or personal-use safety conclusion follows from the reviewed material.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- FDA staff review: CJC-1295 related substances, 2024 ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Five related forms; pharmacology; human safety and marketing
- Teichman et al. 2006: CJC-1295 in healthy adults ↗Accessed 2026-11-10 · abstract_only
Repository abstract; DOI 10.1210/jc.2005-1536
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.